Platelet-derived growth factor enhances platelet recovery in a murine model of radiation-induced thrombocytopenia and reduces apoptosis in megakaryocytes via its receptors and the PI3-k/Akt pathway

Haematologica

Volumn 95, Issue 10, 2010, Pages 1745-1753

  Ye, Jie Yu ^a   Chan, Godfrey Chi Fung ^a   Qiao, Liang ^b   Lian, Qizhou ^a   Meng, Fan Yi ^c   Luo, Xue Qun ^d   Khachigian, Levon M ^e   Ma, Ming ^a   Deng, Ruixia ^a   Chen, Jian Liang ^a   Chong, Beng H ^e   Yang, Mo ^a,c,d  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF SYDNEY   (Australia)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

^d THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Apoptosis; Imatinib mesylate; Platelet derived growth factor; Thrombocytopenia; Thrombopoiesis

Indexed keywords

CASPASE 3; IMATINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE B; THROMBOPOIETIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW; BURST FORMING UNIT E; COLONY FORMING UNIT; COLONY FORMING UNIT F; COLONY FORMING UNIT GEMM; COLONY FORMING UNIT GM; COLONY FORMING UNIT MEGAKARYOCYTE; COLONY FORMING UNIT MK; CONTROLLED STUDY; ERYTHROCYTE COUNT; EXPERIMENTAL MODEL; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HISTOPATHOLOGY; IN VIVO STUDY; IRRADIATION; LEUKOCYTE COUNT; MALE; MEGAKARYOCYTE; MEGAKARYOPOIESIS; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RADIATION INDUCED THROMBOCYTOPENIA; RADIATION PROTECTION; SIGNAL TRANSDUCTION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS;

ANIMALS; APOPTOSIS; BLOOD PLATELETS; MEGAKARYOCYTES; MICE; PHOSPHATIDYLINOSITOL 3-KINASES; PLATELET-DERIVED GROWTH FACTOR; PROTO-ONCOGENE PROTEINS C-AKT; THROMBOCYTOPENIA; WHOLE-BODY IRRADIATION;

EID: 77957771466     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.020958     Document Type: Article

References (46)

1. Ross R, Glomset J, Kariya B, Harker L. A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc Natl Acad Sci USA. 1974;71(4):1207-1210.
2. Bergsten E, Uutela M, Li X, Pietras K, Ostman A, Heldin CH, et al. PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor. Nat Cell Biol. 2001; 3(5):512-516.
3. Gilbertson DG, Duff ME, West JW, Kelly JD, Sheppard PO, Hofstrand PD, et al. Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGF alpha and beta receptor. J Biol Chem. 2001;276(29):27406-27414.
4. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Gene Dev. 2008;22(10): 1276-1312.
5. Leveen P, Pekny M, Gebremedhin S, Swolin B, Larsson E, Betsholtz C. Mice deficient for PDGF-B show renal, cardiovascular, and hematological abnormalities. Gene Dev. 1994;8(16):1875-1887.
6. Kaminski WE, Lindahl P, Lin NL, Broudy VC, Crosby JR, Hellstrom M, et al. Basis of hematopoietic defects in platelet-derived growth factor (PDGF)-B and PDGF betareceptor null mice. Blood. 2001;97(7):1990-1998.
7. Dainiak N, Davies G, Kalmanti M, Lawler J, Kulkarni V. Platelet-derived growth-factor promotes proliferation of erythropoietic progenitor cells - in vitro. J Clin Invest. 1983;71(5):1206-1214.
8. Yang M, Li K, Lam AC, Yuen PMP, Fok TF, Chesterman CN, et al. Platelet-derived growth factor enhances granulopoiesis via bone marrow stromal cells. Int J Hematol. 2001;73(3):327-334.
9. Su RJ, Li K, Yang M, Zhang XB, Tsang KS, Fok TF, et al. Stem cell expansion - platelet-derived growth factor enhances ex vivo expansion of megakaryocytic progenitors from human cord blood. Bone Marrow Transplant. 2001;27(10):1075-1080.
10. Yang M, Chesterman CN, Chong BH. Recombinant PDGF enhances megakaryocytopoiesis in-vitro. Br J Haematol. 1995;91(2):285-289.
11. Su RJ, Zhang XB, Li K, Yang M, Li CK, Fok TF, et al. Platelet-derived growth factor promotes ex vivo expansion of CD34+ cells from human cord blood and enhances longterm culture-initiating cells, non-obese diabetic/severe combined immunodeficient repopulating cells and formation of adherent cells. Br J Haematol. 2002;117(3):735-746.
12. Su RJ, Li K, Zhang XB, Yuen PMP, Li CK, James AE, et al. Platelet-derived growth factor enhances expansion of umbilical cord blood CD34(+) cells in contact with hematopoietic stroma. Stem Cells Dev. 2005;14(2):223-230.
13. Yang M, Khachigian LM, Hicks C, Chesterman CN, Chong BH. Identification of PDGF receptors on human megakaryocytes and megakaryocytic cell lines. Thromb Haemostasis. 1997;78(2):892-896.
14. Vassbotn FS, Havnen OK, Heldin CH, Holmsen H. Negative feedback-regulation of human platelets via autocrine activation of the platelet-derived growth-factor alpha-receptor. J Biol Chem. 1994;269(19):13874-13879.
15. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408-2417.
16. van Deventer HW, Hall MD, Orlowski RZ, Mitchell BS, Berkowitz LR, Hogan C, et al. Clinical course of thrombocytopenia in patients treated with imatinib mesylate for accelerated phase chronic myelogenous leukemia. Am J Hematol. 2002;71(3):184-190.
17. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, et al. Abl proteintyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 2000;295(1): 139-145.
18. Soroceanu L, Akhavan A, Cobbs CS. Platelet-derived growth factor-alpha receptor activation is required for human cytomegalovirus infection. Nature. 2008; 455(7211):391-395.
19. Servidei T, Riccardi A, Sanguinetti M, Dominici C, Riccardi R. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor ST1571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and ST1571-induced Akt inactivation. J Cell Physiol. 2006;208(1):220-228.
20. Cristofanilli M, Morandi P, Krishnamurthy S, Reuben JM, Lee BN, Francis D, et al. Imatinib mesylate (Gleevec (R)) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations. Ann Oncol. 2008;19(10):1713-1719.
21. Fierro F, Illmer T, Jing D, Schleyer E, Ehninger G, Boxberger S, et al. Inhibition of platelet-derived growth factor receptor beta by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro. Cell Proliferat. 2007;40(3):355-366.
22. Chui CMY, Li K, Yang M, Chuen CKY, Fok TF, Li CK, et al. Platelet-derived growth factor up-regulates the expression of transcription factors NF-E2, GATA-1 and c-Fos in megakaryocytic cell lines. Cytokine. 2003; 21(2):51-64.
23. Heldin CH, Ostman A, Ronnstrand L. Signal transduction via platelet-derived growth factor receptors. Biochim Biophys Acta. 1998;1378(1):F79-F113.
24. Hopfner M, Schuppan D, Scherubl H. Growth factor receptors and related signaling pathways as targets for novel treatment strategies of hepatocellular cancer. World J Gastroenterol. 2008;14(1):1-14.
25. Yang M, Chan GC, Deng R, Ng MH, Cheng SW, Lau CP, et al. An herbal decoction of Radix astragali and Radix angelicae sinensis promotes hematopoiesis and thrombopoiesis. J Ethnopharmacol. 2009;124(1): 87-97.
26. Yang M, Li K, Ng PC, Chuen CKY, Lau TK, Cheng YS, et al. Promoting effects of serotonin on hematopoiesis: Ex vivo expansion of cord blood CD34(+) stem/progenitor cells, proliferation of bone marrow stromal cells, and antiapoptosis. Stem Cells. 2007; 25(7):1800-1806.
27. Li K, Sung RYT, Huang WZ, Yang M, Pong NH, Lee SM, et al. Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin. Circulation. 2006;113(18):2211-2220.
28. Yang M, Li K, Chui CM, Yuen PM, Chan PK, Chuen CK, et al. Expression of interleukin (IL) 1 type I and type II receptors in megakaryocytic cells and enhancing effects of IL-1beta on megakaryocytopoiesis and NF-E2 expression. Br J Haematol. 2000; 111(1):371-380.
29. Rolny C, Nilsson I, Magnusson P, Armulik A, Jakobsson L, Wentzel P, et al. Platelet-derived growth factor receptor-beta promotes early endothelial cell differentiation. Blood. 2006;108(6):1877-1886.
30. Hoch RV, Soriano P. Roles of PDGF in animal development. Development. 2003; 130(20):4769-4784.
31. Demoulin JB, Seo JK, Ekman S, Grapengiesser E, Hellman U, Ronnstrand L, et al. Ligand-induced recruitment of Na+/H+-exchanger regulatory factor to the PDGF (platelet-derived growth factor) receptor regulates actin cytoskeleton reorganization by PDGF. Biochem J. 2003; 376(Pt 2):505-510.
32. Langley RR, Fan D, Tsan RZ, Rebhun R, He J, Kim SJ, et al. Activation of the platelet-derived growth factor-receptor enhances survival of murine bone endothelial cells. Cancer Res. 2004;64(11):3727-3730.
33. KauffmanZeh A, RodriguezViciana P, Ulrich E, Gilbert C, Coffer P, Downward J, et al. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature. 1997;385(6616):544-548.
34. White BC, Sullivan JM, DeGracia DJ, O'Neil BJ, Neumar RW, Grossman LI, et al. Brain ischemia and reperfusion: molecular mechanisms of neuronal injury. J Neurol Sci. 2000;179(S 1-2):1-33.
35. Kuida K, Haydar TF, Kuan CY, Gu Y, Taya C, Karasuyama H, et al. Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9. Cell. 1998;94(3):325-337.
36. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science. 1998;282 (5392):1318-1321.
37. Cohen MH, Farrell A, Justice R, Pazdur R. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Oncologist. 2009;14(2):174-180.
38. Reardon DA, Egorin MJ, Quinn JA, Rich JN, Gururangan S, Vredenburgh JJ, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol. 2005;23(36): 9359-9368.
39. Agis H, Jaeger E, Doninger B, Sillaber C, Marosi C, Drach J, et al. In vivo effects of imatinib mesylate on human haematopoietic progenitor cells. Eur J Clin Invest. 2006;36(6):402-408.
40. Bartolovic K, Balabanov S, Hartmann U, Komor M, Boehmler AM, Buhring HJ, et al. Inhibitory effect of imatinib on normal progenitor cells in vitro. Blood. 2004;103(2): 523-529.
41. Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol. 2009;27(18):3027-3035.
42. Deremer DL, Ustun C, Natarajan K. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin Ther. 2008;30(11):1956-1975.
43. Lev PR, Marta RF, Vassallu P, Molinas FC. Variation of PDGF, TGFbeta, and bFGF levels in essential thrombocythemia patients treated with anagrelide. Am J Hematol. 2002;70(2):85-91.
44. Suzuki A, Miyagawa-Tomita S, Komatsu K, Nakazawa M, Fukaya T, Baba K, et al. Immunohistochemical study of apparently intact coronary artery in a child after Kawasaki disease. Pediatr Int. 2004;46(5): 590-596.
45. Wang H, Cheng P. Kawasaki disease on PDGF expression and VSMC proliferation. J Tongji Med Univ. 1998;18(4):243-246.
46. Reilly JT. Idiopathic myelofibrosis: pathogenesis, natural history and management. Blood Rev. 1997;11(4):233-242.